RYTM - Rhythm Pharmaceuticals Inc. (RYTM) Q4 2023 Earnings Call Transcript

2024-02-22 23:33:09 ET

Rhythm Pharmaceuticals, Inc. (RYTM)

Q4 2023 Earnings Conference Call

February 22, 2024 08:00 AM ET

Company Participants

David Connolly - Executive Director, IR and Corporate Communications

David Meeker - Chairman, President, and CEO

Jennifer Lee - Executive Vice President, Head of North America

Hunter Smith - Chief Financial Officer

Yann Mazabraud - Executive Vice President, Head of International

Conference Call Participants

Tazeen Ahmad - Bank of America

Corinne Jenkins - Goldman Sachs

Derek Archila - Wells Fargo

Phil Nadeau - TD Cowen

Whitney Ijem - Canaccord Genuity

Dae Gon Ha - Stifel

Joseph Stringer - Needham

Michael Higgins - Ladenburg Thalmann

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Rhythm Pharmaceuticals Fourth Quarter and Full Year 2023 Earnings Conference Call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would like now to turn the conference over to David Connolly, Investor Relations and Corporate Communications. Please go ahead.

David Connolly

Thank you, Michelle. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section on the Investors page of our website, ir.rhythmtx.com.

This morning, we issued a press release that provides our Q4 year end 2023 financial results and a business update, which is available on our website. As listed on Slide 2 is our agenda. Here with me today in Boston are David Meeker, Chair, Chief Executive Officer and President of Rhythm Pharmaceuticals; Jennifer Li, Executive Vice President, Head of North America; Hunter Smith, our Chief Financial Officer; and Yann Mazabraud, Executive Vice President, Head of International is on the line joining us from Europe.

And on Slide 3, I'll remind you that this call contains remarks concerning future expectations, plans and prospects, which constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual or quarterly reports on file with the SEC. In addition, any forward-looking statements represent our views as of only today and should not be relied upon as representing our views as of any subsequent dates. We specifically disclaim any obligation to update such statements.

With that, I'll turn the call over to David Meeker, who will begin on Slide 5.

David Meeker

Thank you, Dave. Good morning, everyone, and thank you for joining the call. So 2023 was truly a transformational year for Rhythm commercially, developmentally, financially and strategically as we have expanded potential indication to meaningful next generation products. 2024 will be a year focused on execution, setting up an exciting year of milestone achievements in 2025....

For further details see: